Article
Progress in determining response to treatment in gastrointestinal stromal tumor.
Expert review of anticancer therapy - 1 Apr 2020
Arshad Junaid, Ahmed Jibran, Subhawong Ty, Trent Jonathan C
Abstract excerpt
Introduction: Gastrointestinal stromal tumor (GIST) is the most common malignant mesenchymal tumor of the gastrointestinal system. Multiple advances in the management of GIST from the discovery of KIT/PDGRA and other genetic alterations have led to the development of multiple tyrosine kinase inhibitors. Response assessment in GIST is determined with iRECIST (Response Evaluation Criteria in Solid Tumors), PERCIST...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.